Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Long-Term Immunotherapy for Alveolar Soft Part Sarcoma

AMA Data Show Nearly 50 Percent of Surveyed Oncologists Reported Burnout in 2025

Unique Phase I NSCLC Trial Sites Decreasing in United States

Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer